Shares of Azitra, Inc. (NYSE: AZTR) experienced a remarkable surge on the US stock charts today, following the announcement of a strategic global initiative. As of the latest check during the current market session, AZTR stock had soared by 529.63%, reaching a value of $10.20.
Patent Milestones and Global Reach
Azitra (AZTR) disclosed that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,036,248. This patent pertains to future potential pipeline candidates for conditions such as atopic dermatitis, under the title “Therapeutic treatment of skin disease with recombinant skin microorganisms.”
In addition, Azitra revealed that three more patents have been newly approved in the United States, Canada, and China. The first U.S. patent describes the makeup of *Staphylococcus epidermidis* strains that secrete filaggrin. The Chinese patent relates to the composition of these strains, whereas the Canadian patent addresses their application in the treatment of atopic dermatitis and other skin conditions.
Progress in Dermatological Medicine
With the clearance of three more patents in important markets and the second U.S. patent issued this year, Azitra’s market presence in the United States, Canada, and China has greatly increased. Azitra specializes in developing live biotherapeutic product candidates aimed at treating various skin diseases with precision dermatology. Notably, many patients with atopic dermatitis suffer from missing or abnormal levels of filaggrin.
Azitra is pioneering a novel topical treatment modality for filaggrin-deficient diseases, which directly addresses the disease’s pathophysiology by delivering filaggrin to the skin. This treatment comprises a functional unit of the human filaggrin protein paired with a cell-penetrating peptide, aiming to provide stable filaggrin delivery via topical application and enhance skin penetration.
Expanding Intellectual Property Portfolio
Azitra’s intellectual property portfolio presently consists of four awarded U.S. patents, fourteen granted international patents, nine pending U.S. patent applications, and forty-four pending international patent applications, following the most recent approvals of two U.S., two Chinese, and Canadian patents. These advancements demonstrate Azitra’s dedication to developing dermatological therapies and growing its presence internationally.